Jump to content

Taisho Pharmaceutical: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
nihongo, TSE, link, Category, ja:大正製薬
Line 5: Line 5:


==Products==
==Products==
The company's most successful product to date has been the [[macrolide]] [[antibiotic]] [[clarithromycin]]. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed [[Abbott Laboratories]].
The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, and others.
In prescription pharmaceuticals, the company's most successful product to date has been the [[macrolide]] [[antibiotic]] [[clarithromycin]]. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed [[Abbott Laboratories]].


==Ownership==
==Ownership==

Revision as of 18:32, 10 April 2007

Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha) (TYO: 4535) is a Japanese pharmaceutical company based in Tokyo.

History

Taisho was established in 1912 to produce over-the-counter drugs. The company moved into prescription drug R&D in 1955.

Products

The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, and others. In prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed Abbott Laboratories.

Ownership

Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange where its security code is 4535.

External links